Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18:785–802.
Article PubMed PubMed Central Google Scholar
Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang ZG, et al. China Hypertension Survey Investigators. Status of hypertension in China: Results from the China Hypertension Survey, 2012-2015. Circulation. 2018;137:2344–56.
Chen X, Xu SK, Guo QH, Hu Z, Wang HY, Yu J, et al. Barriers to blood pressure control in China in a large opportunistic screening. J Clin Hypertens. 2020;22:835–41.
Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind placebo-controlled, active comparator study. Lancet. 2010;375:1255–66.
Article CAS PubMed Google Scholar
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–20.
Article CAS PubMed Google Scholar
Wang TD, Chiang CE, Chao TH, Cheng HM, Wu YW, Wu YJ, et al. 2022 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. Acta Cardiol Sin. 2022;38:225–325.
PubMed PubMed Central Google Scholar
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee of clinical practice guidelines. Circulation. 2022;145:e895–1032.
Li Y, Li XH, Huang ZJ, Yang GP, Zhang GG, Zhao SP, et al. A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk. PLoS One. 2015;10:e0117560.
Article PubMed PubMed Central Google Scholar
Sun JC, Xu WJ, Hua HJ, Xiao Y, Chen XY, Gao ZW, et al. Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor. Biomed Pharmacother. 2020;19:110410.
Hu Y, Zhang H, Li XJ, Mai JJ, Yang LZ, Yan J, et al. A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers. Expert Opin Investig Drugs. 2022;31:977–85.
Article CAS PubMed Google Scholar
Huo Y, Li WM, Webb R, Zhao L, Wang Q, Guo WN. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2019;21:67–76.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: A randomized, double-blind, multicenter study. Hypertens Res. 2022;45:824–33.
Article CAS PubMed PubMed Central Google Scholar
Wang JG, Yukisada K, Sibulo A Jr, Hafeez K, Jia Y, Zhang J. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. J Hypertens. 2017;35:877–85.
Article CAS PubMed Google Scholar
Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013;34:886–93c.
Article CAS PubMed Google Scholar
Campese VM, Lasseter KC, Ferrario CM, Smith WB, Ruddy MC, Grim CE, et al. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension. 2001;38:1342–8.
Article CAS PubMed Google Scholar
Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;133:1115–24.
Article CAS PubMed PubMed Central Google Scholar
Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698–705.
Article CAS PubMed Google Scholar
Yano Y, Tanner RM, Sakhuja S, Jaeger BC, Booth JN 3rd, Abdalla M, et al. Association of daytime and nighttime blood pressure with cardiovascular disease events among African American individuals. JAMA Cadiol. 2019;4:910–7.
Kario K, Hoshide S, Mizuno H, Kabutoya T, Nishizawa M, Yoshida T, et al. Nighttime blood pressure phenotype and cardiovascular prognosis: Practitioner-based nationwide JAMP study. Circulation. 2020;142:1810–20.
Article CAS PubMed PubMed Central Google Scholar
Li Y, Wang JG. Isolated nocturnal hypertension: a disease masked in the dark. Hypertension. 2013;61:278–83.
Article CAS PubMed Google Scholar
Sun NL, Jiang YN, Wang HY, Yuan YF, Cheng WL, Han QH, et al. Survey on sodium and potassium intake in patients with hypertension in China. J Clin Hypertens (Greenwich). 2021;23:1957–64.
Article CAS PubMed Google Scholar
Du SF, Wang HJ, Zhang B, Popkin BM. Dietary potassium intake remains low and sodium intake remains high, and most sodium is derived from home food preparation for Chinese adults, 1991-2015 trends. J Nutr. 2020;150:1230–9.
Article PubMed PubMed Central Google Scholar
Gardner DG, Chen S, Glenn DJ, Grigsby CL. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension. 2007;49:419–26.
留言 (0)